PUBLISHER: Grand View Research | PRODUCT CODE: 1554035
PUBLISHER: Grand View Research | PRODUCT CODE: 1554035
The global bariatric surgery devices market size is expected to reach USD 3.64 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing incidence rate of obesity has led to many government initiatives at regional as well as global level to increase awareness related to obesity and undertake various incidence curbing action plans. For instance, the South Wales government launched the NSW Healthy Eating and Active Living Strategy 2013-2018 for preventing obesity.
In addition, to strategic planning, the governments of developed nations are also funding universities to design strategic interventions to control rising obesity. For the year 2014, New Zealand invested USD 40 million for its Healthy Families NZ anti-obesity initiative. Moreover, industry players are also trying to tackle the rising problem of obesity by launching new products. In February 2017, a startup company, Allurion Technologies, located in Massachusetts, U.S. filed a regulatory filing to report the USD 19 million raised amount out of the target of USD 27 million. The funds were intended to use for the development of non-endoscopic gastric balloon, Ellipse. This device is in the form of a capsule which when swallowed, is inflated in the stomach and deflates after months and is passed out without the need for anesthesia for its removal. This device is anticipated to revolutionize the bariatric surgery devices market due to its ease of use over the forecast period
The demand for non-invasive surgeries is also increasing, as non-invasive surgeries save time, cost, and decrease hospital stay. Governments are also encouraging the use of more incisionless surgeries in order to decrease the cases of infection. For instance, in July 2015, the FDA approved a balloon device, where the balloon is directly swallowed using a sterile solution.